Bendamustine
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-BENDAMUSTINE |
|---|---|
| Type | Drug |
| Aliases | BendekaLevactTreandaБендамустин |
| Status | reviewed 2026-04-24 | pending_clinical_signoff |
| Diseases | DIS-ALCL DIS-DLBCL-NOS DIS-FL DIS-HCV-MZL DIS-NODAL-MZL DIS-SPLENIC-MZL |
| Sources | SRC-ESMO-MZL-2024 SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Nitrogen mustard alkylating agent with purine analogue properties |
|---|---|
| Mechanism | Bifunctional alkylating agent with a purine-like benzimidazole moiety; induces DNA damage and apoptosis in lymphocytes. |
| Typical dosing | 90 mg/m² IV days 1-2 of 28-day cycle (with rituximab) |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Dose adjustment needed for FIB-4 > 3.25 or cirrhosis (see Regimen.dose_adjustments in REG-BR-STANDARD).
Used By
Contraindications
CI-SEVERE-CYTOPENIA-BR- CI-SEVERE-CYTOPENIA-BR
Regimens
REG-BENDAMUSTINE-PTCL- Bendamustine monotherapy 90 mg/m² days 1+2 q21d — r/r PTCL incl ALCLREG-BR-STANDARD- Bendamustine + Rituximab (BR), 6 cyclesREG-OBINUTUZUMAB-BENDA- Obinutuzumab + Bendamustine (GADOLIN)REG-POLA-R-BENDAMUSTINE- Polatuzumab vedotin + Rituximab + Bendamustine (Pola-BR), 6 cyclesREG-R-BENDAMUSTINE-RELAPSED-MZL- R-Bendamustine for relapsed marginal zone lymphoma (post-rituximab failure)